This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

NCT03944447

Conditions

1. Chronic Pain
2. Chronic Pain Syndrome
3. Chronic Pain Due to Injury
4. Chronic Pain Due to Trauma
5. Fibromyalgia
6. Seizures
7. Hepatitis C
8. Cancer
9. Crohn Disease
10. HIV/AIDS
11. Multiple Sclerosis
12. Traumatic Brain Injury
13. Sickle Cell Disease
14. Post Traumatic Stress Disorder
15. Tourette Syndrome
16. Ulcerative Colitis
17. Glaucoma
18. Epilepsy
19. Inflammatory Bowel Diseases
20. Parkinson Disease
21. Amyotrophic Lateral Sclerosis
22. Chronic Traumatic Encephalopathy
23. Anxiety
24. Depression
25. Insomnia
26. Autism
27. Opioid-use Disorder
28. Bipolar Disorder
29. Covid19
30. SARS-CoV Infection
31. COVID-19
32. Corona Virus Infection
33. Coronavirus

Interventions

1. Drug: Cannabis, Medical

MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Moto Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic

HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare. The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients. Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity. Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients. We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.

NCT04320472

Conditions

1. COVID-19
2. Encephalopathy
3. Critically Ill

Interventions

1. Other: Follow up

MeSH:Brain Diseases Critical Illness

HPO:Encephalopathy

Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.

NCT04359914

Conditions

1. Critical Illness
2. COVID-19
3. Central Nervous System Injury
4. Delirium
5. Encephalopathy

MeSH:Delirium Brain Diseases Trauma, Nervous System Critical Illness

HPO:Encephalopathy

The SARS-CoV-2 infection was detected in December 2019 in Wuhan City, China. The infection affects all age groups, although childhood is the lowest proportion of those affected. The main clinical manifestations that require hospitalization of infected patients are SARS pneumonia, which may require treatment in the intensive care unit (27%) and its progression into acute respiratory distress syndrome (67%) with life-threatening conditions in almost 25% of patients diagnosed with "SARS-CoV-2 infection". Nervous system damage with SARS-CoV-2 infection has been practically not investigated, but neurological disorders have been reported in 36% of these patients. Finally, the mortality rate associated with the new virus is high in patients who require treatment in intensive care units (62% of cases). Therefore, we are conducting a prospective study to identify acute encephalopathy predictors in patients with COVID-19.

NCT04405544

Conditions

1. Encephalopathy
2. COVID

Interventions

1. Diagnostic Test: CT-scan
2. Diagnostic Test: EEG
3. Diagnostic Test: EP
4. Diagnostic Test: Pulse oximetry
5. Diagnostic Test: Blood tests

MeSH:Brain Diseases

HPO:Encephalopathy